The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Diagnostic tools for AML
Curtis Lachowiez, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the tools and platforms used for the diagnosis of acute myeloid leukemia (AML). Morphological assessment of the bone marrow is the main diagnostic strategy used to identify the type of leukemia a patient has. As technology has advanced, several additional tools are used to provide more detail on a patient’s disease. Cytogenetic and molecular genetic analyses are conducted using fluorescence in situ hybridization (FISH), next-generation sequencing, and flow cytometry. Dr Lachowiez explains the extra information that can be provide by the identification of prognostic and predictive genetic changes using these techniques. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
